652 related articles for article (PubMed ID: 35715860)
41. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
42. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway.
Liu CY; Xu JY; Shi XY; Huang W; Ruan TY; Xie P; Ding JL
Lab Invest; 2013 Jul; 93(7):844-54. PubMed ID: 23752129
[TBL] [Abstract][Full Text] [Related]
43. MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis.
Wang J; Li M; Han X; Wang H; Wang X; Ma G; Xia T; Wang S
Cell Death Dis; 2020 Jul; 11(7):500. PubMed ID: 32620748
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
[TBL] [Abstract][Full Text] [Related]
45. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
[TBL] [Abstract][Full Text] [Related]
46. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway inhibition.
Xiao G; Lu W; Yuan J; Liu Z; Wang P; Fan H
J Transl Med; 2024 Jan; 22(1):99. PubMed ID: 38268032
[TBL] [Abstract][Full Text] [Related]
47. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
48. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
49. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
50. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
51. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
52. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT.
Nie J; Jiang HC; Zhou YC; Jiang B; He WJ; Wang YF; Dong J
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1062-1071. PubMed ID: 30950326
[TBL] [Abstract][Full Text] [Related]
53. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
54. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.
Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL
Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232
[TBL] [Abstract][Full Text] [Related]
56. Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.
Bowers LW; Rossi EL; McDonell SB; Doerstling SS; Khatib SA; Lineberger CG; Albright JE; Tang X; deGraffenried LA; Hursting SD
Mol Cancer Res; 2018 May; 16(5):869-879. PubMed ID: 29453319
[TBL] [Abstract][Full Text] [Related]
57. Curcumin suppresses metastasis of triple-negative breast cancer cells by modulating EMT signaling pathways: An integrated study of bioinformatics analysis.
Chen Z; Lu P; Li M; Zhang Q; He T; Gan L
Medicine (Baltimore); 2024 Feb; 103(8):e37264. PubMed ID: 38394486
[TBL] [Abstract][Full Text] [Related]
58. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
[TBL] [Abstract][Full Text] [Related]
59. Targeting FAPα-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
Li X; Chen M; Lu W; Tang J; Deng L; Wen Q; Huang M; Deng R; Ye G; Ye W; Zhang D
Cancer Lett; 2021 Apr; 503():32-42. PubMed ID: 33482262
[TBL] [Abstract][Full Text] [Related]
60. AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism.
Vitaliti A; Roccatani I; Iorio E; Perta N; Gismondi A; Chirico M; Pisanu ME; Di Marino D; Canini A; De Luca A; Rossi L
Cell Oncol (Dordr); 2023 Feb; 46(1):93-115. PubMed ID: 36454513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
